Results 1 to 10 of about 86,999 (210)
Cytologic identification of serous neoplasms in peritoneal fluids [PDF]
Cancer, 2001 Recognition of serous neoplasms in peritoneal fluids and their subclassification into serous borderline tumors (SBT) and serous carcinomas (SCA) may be difficult. The objective of this study was to determine whether morphologic criteria can distinguish reactive mesothelial cells (RM), SBT, and SCA (grades 1-3) in peritoneal fluids.A blinded review of ...
Debra A Bell
exaly +3 more sources
Enigma portal: Peritoneal effusion in a patient with a myeloproliferative neoplasm
Cytopathology, 2022 Quiz regarding the cytological analysis of peritoneal effusion in a patient with a history of myeloproliferative neoplasm.
Frankel, Diane +5 more
openaire +3 more sources
Cytokines in peritoneal fluid of ovarian neoplasms
Journal of Obstetrics and Gynaecology, 2019 The aim of this study was to evaluate cytokine levels (IL-2, IL-8, TNF-α, IL-5, IL-6 and IL-10) in the peritoneal fluid in non-neoplastic tumours, benign ovarian neoplasms and malignant ovarian neoplasms. Peritoneal fluid or ascites was collected from 117 patients with neoplastic and non-neoplastic ovarian tumours.
Cid Almeida, de Lima +6 more
openaire +2 more sources
Molecular Oncology, EarlyView.We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric +10 more
wiley +1 more source
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
FEBS Open Bio, EarlyView.Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel +8 more
wiley +1 more source
Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms
PLoS ONE, 2012 Power morcellation has become a common technique for the minimally invasive resection of uterine leiomyomas. This technique is associated with dissemination of cellular material throughout the peritoneum. When morcellated uterine tumors are unexpectedly found to be leiomyosarcomas or tumors with atypical features (atypical leiomyoma, smooth muscle ...
Seidman, Michael A. +5 more
openaire +6 more sources
Aggressive Management of Peritoneal Carcinomatosis from Mucinous Appendiceal Neoplasms [PDF]
Annals of Surgical Oncology, 2012 Peritoneal carcinomatosis (PC) in the setting of mucinous appendiceal neoplasms is characterized by the intraperitoneal accumulation of mucinous ascites and mucin-secreting epithelial cells that leads to progressive compression of intra-abdominal organs, morbidity, and eventual death.
Frances, Austin +11 more
openaire +2 more sources
Advanced Science, EarlyView.A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source